GSK3368715 (GSK-3368715; EPZ-019997; EPZ019997) is a novel, orally bioactive, and reversible inhibitor of type I PRMTs (protein arginine methyltransferases) with potential antitumor activity.

3-deazaneplanocin A HCl (known also as DZNep; C-c3Ado; NSC-617989), the hydrochloride salt of 3-deazaneplanocin A which is an adenosine analog, is a novel and competitive inhibitor of S-adenosylhomocysteine hydrolase and also an EZH2 (histone methyltransferase) inhibitor with anticancer activity.

CPI-360 is a novel, highly potent, selective, and SAM-competitive inhibitor of enhancer of zeste homolog 2 (EZH2) with potential antitumor activity.

AMI-1 (AMI 1) disodium salt is a novel, cell-permeable and selective inhibitor of Histone Methyltransferase (HMT) with anti-inflammatory activity.

Dot1L-IN-4 is a novel and potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor.

BAY-598 (BAY598 S-isomer) is novel, potent, selective and peptide-competitive small molecule inhibitor of lysine methyltransferase SMYD2 with potential antitumor activity.

UNC0646 is a novel, potent and selective histone methyltransferase G9a inhibitor with IC50 of 6 nM.